Heart Test Laboratories (NASDAQ:HSCS) Earns “Buy” Rating from Maxim Group

Maxim Group reiterated their buy rating on shares of Heart Test Laboratories (NASDAQ:HSCS) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $12.00 target price on the stock.

Separately, Ascendiant Capital Markets reissued a “buy” rating and set a $15.00 price target on shares of Heart Test Laboratories in a report on Monday, September 23rd.

Heart Test Laboratories Stock Performance

HSCS opened at $3.83 on Wednesday. The company’s 50 day moving average is $3.24 and its 200 day moving average is $3.78. The company has a current ratio of 4.49, a quick ratio of 4.02 and a debt-to-equity ratio of 0.08. The company has a market cap of $3.50 million, a price-to-earnings ratio of -0.18 and a beta of 3.23. Heart Test Laboratories has a 12-month low of $2.36 and a 12-month high of $18.50.

Heart Test Laboratories (NASDAQ:HSCS) last issued its quarterly earnings results on Monday, December 16th. The company reported ($2.27) earnings per share for the quarter, topping the consensus estimate of ($2.30) by $0.03. During the same quarter in the previous year, the firm posted ($15.92) EPS. On average, equities research analysts predict that Heart Test Laboratories will post -9.82 EPS for the current year.

Heart Test Laboratories Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.